Status:
APPROVED_FOR_MARKETING
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Primary Hyperoxaluria
Eligibility:
All Genders
Brief Summary
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
Detailed Description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more abou...
Eligibility Criteria
Inclusion
- Documented diagnosis of Primary Hyperoxaluria Type 1
Exclusion
- Clinically significant health concerns (with the exception of PH1)
- Received an investigational agent within 30 days before the first dose of lumasiran or are in follow-up of another clinical study
- Previously or currently participating in lumasiran clinical study
- History of liver transplant
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04125472
Last Update
February 16 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.